Dabrafenib · Regulatory label update

FDA supplemental approval: Tafinlar (Labeling)

U.S. Food and Drug Administration · March 26, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is a U.S. FDA supplemental approval for labeling changes to Tafinlar (dabrafenib), a BRAF inhibitor. The record does not contain clinical trial results, efficacy data, or information on what specific labeling changes were made.

What was studied

Regulatory label update. United States.

Key findings

Safety

This is a regulatory approval record, not a clinical study; no trial outcomes, efficacy data, or safety results are reported.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval for labeling changes to an established BRAF inhibitor; does not report clinical trial outcomes or efficacy data.

Study design

As stated by the source record.

SettingUnited States

Caveats

This is a regulatory approval record, not a clinical study; no trial outcomes, efficacy data, or safety results are reported.
The specific labeling changes approved are not described in this record.
No clinical population, comparator, or endpoint information is provided.
The record does not indicate which labeling revision or clinical question prompted this supplement.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory record; no clinical study design reported.

Directness

insufficient

Labeling action does not specify clinical endpoint or patient population affected.

Consistency

insufficient

No comparative data or prior outcomes referenced in this record.

Risk of bias

insufficient

Regulatory approval record; no bias assessment applicable.

Sample adequacy

insufficient

No clinical study sample reported; labeling supplement only.

What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application NDA217514. This is a regulatory action record, not a clinical study. Brand name: TAFINLAR. Active ingredient: DABRAFENIB. Sponsor: NOVARTIS. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-03-26. Products: TAFINLAR, CAPSULE, ORAL, DABRAFENIB MESYLATE 75MG; TAFINLAR, TABLET, ORAL SUSPENSION, DABRAFENIB MESYLATE 10MG; TAFINLAR, TABLET, FOR SUSPENSION, ORAL, DABRAFENIB MESYLATE EQ 10MG BASE.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NovartisDabrafenib